Ghrelin and cardiovascular diseases

Summary In 1999, a peptide from the stomach called ghrelin was discovered, which exerts potent growth hormone releasing powers. Subsequent studies revealed that it exerts a potent orexigenic action. In addition, the beneficial effects of ghrelin in cardiovascular diseases have been recently suggeste...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiology Vol. 59; no. 1; pp. 8 - 13
Main Authors Kishimoto, Ichiro, MD, PhD, Tokudome, Takeshi, MD, PhD, Hosoda, Hiroshi, MD, PhD, Miyazato, Mikiya, MD, PhD, Kangawa, Kenji, PhD
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.01.2012
Subjects
Animals
Cardiovascular
Cardiovascular Diseases - drug therapy
Ghrelin
Ghrelin - pharmacology
Ghrelin - physiology
Ghrelin - therapeutic use
GHS receptor
Heart failure
Humans
Myocardial infarction
Pulmonary hypertension
Sympathetic nerve
Vagus nerve
Heart failure
Myocardial infarction
Sympathetic nerve
Ghrelin
GHS receptor
Vagus nerve
Pulmonary hypertension
Online AccessGet full text

Cover

More Information
Summary:Summary In 1999, a peptide from the stomach called ghrelin was discovered, which exerts potent growth hormone releasing powers. Subsequent studies revealed that it exerts a potent orexigenic action. In addition, the beneficial effects of ghrelin in cardiovascular diseases have been recently suggested. In humans as well as in animals, administration of ghrelin improves cardiac function and remodeling in chronic heart failure. In an animal model for myocardial infarction, ghrelin treatment early after coronary ligation effectively reduces fatal arrhythmia and, consequently, mortality, suggesting the potential therapeutic role of the peptide in acute myocardial infarction. Although how ghrelin may influence the cardiovascular system is not fully understood, the cardiovascular beneficial effects are mediated possibly through a combination of various actions, such as an increase in growth hormone level, an improvement in energy balance, direct actions to the cardiovascular cells, and regulation of the autonomic nervous activity. Of note, current experimental evidence suggests that ghrelin may act centrally to decrease sympathetic nervous system activity through peripheral afferent nerve. Thus, administration of ghrelin might become a unique new therapy for cardiovascular diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2011.11.002